TL;DR
The best-known weight-loss shots, semaglutide (Wegovy) and tirzepatide, are taken weekly, and in trials, when people stopped them, most of the lost weight came back. A Chinese drugmaker, Gan & Lee Pharmaceuticals, says it has a way to keep it off with one shot a month. On Nov. 4, 2026, the company announced that its final-stage trial of a monthly maintenance dose met its main goal: people who had already lost weight on its drug, bofanglutide, held their weight steady for 24 weeks on monthly shots, while people switched to a dummy shot gained back about 8.5% of their body weight (company claim, not yet peer reviewed). For anyone facing a lifetime of injections, that means 12 injections a year instead of 52, and a real answer to the regain problem. Our odds that a monthly keep-it-off shot is approved in China: a 75% chance it works, likely by 2028. For the full odds and the timeline of breakthroughs that leads to a monthly shot in the U.S., subscribe.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.